1 440 123 ANTIOXIDATIVE EFFECTS OF RHODIOLA GENUS: PHYTOCHEMISTRY AND PHARMACOLOGICAL MECHANISMS AGAINST THE DISEASES. RHODIOLA AS ONE OF TRADITIONAL MEDICINES HAS BEEN USED FOR CLINICAL TREATMENTS DUE TO ITS STRONG ANTIOXIDANT PROPERTIES. PHYTOCHEMICAL ANALYSIS REVEALED THE PRESENCE OF FLAVONOIDS, PHENYLPROPANOIDS, PHENYLETHANOL/BENZYL ALCOHOL DERIVATIVES, CYANOGENIC GLYCOSIDES AND TERPENOIDS. THE BIOACTIVE COMPOUNDS HAD BEEN DEMONSTRATED TO BE EFFECTIVE AT SCAVENGING REACTIVE OXYGEN SPECIES (ROS). THE STRUCTURES CONTAIN PHENOLIC HYDROXYL GROUPS AND UNSATURATED BONDS. THIS ARTICLE REVIEWS ANTIOXIDANT CAPACITIES OF THE EXTRACTS AND BIOACTIVE COMPONENTS DERIVED FROM RHODIOLA PLANTS. AS THE MAJOR PHARMACOLOGICAL INGREDIENT, SALIDROSIDE IS RIGOROUSLY INVESTIGATED AND USED IN SCIENTIFIC RESEARCHES AND CLINICAL PRACTICES. ACCUMULATED EVIDENCES INDICATED THAT EXTRACTS OF RHODIOLA PLANTS OR SALIDROSIDE COULD BE ABLE TO REVERSE DNA DAMAGE AND ALTER EXPRESSION OF CYTOKINES AND ANTIOXIDATIVE ENZYMES INDUCED BY ROS. THE UNDERLYING MECHANISMS FOR THE ANTIOXIDATIVE EFFECTS OF THE HERB HAVE BEEN INVESTIGATED IN THE LAST TWO DECADES. WE SUMMARIZE THE POSSIBLE EFFECTS AND ACTING PATHWAYS FOR THE HERB INVOLVED IN SEVERAL CHRONIC DISEASES IN CARDIOVASCULAR, RESPIRATORY, AND NERVOUS SYSTEMS, AS WELL AS POTENTIAL EPIGENETIC INFLUENCES. THE INFORMATION GENERATED FROM EXPERIMENTAL AND CLINICAL STUDIES OFFERED VALUABLE INSIGHTS FOR FURTHER INVESTIGATIONS OF MEDICAL POTENTIALS OF RHODIOLA PLANTS. 2017 2 5604 31 ROSAVIN AMELIORATES HEPATIC INFLAMMATION AND FIBROSIS IN THE NASH RAT MODEL VIA TARGETING HEPATIC CELL DEATH. BACKGROUND: NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) REPRESENTS THE MOST COMMON FORM OF CHRONIC LIVER DISEASE THAT URGENTLY NEEDS EFFECTIVE THERAPY. ROSAVIN, A MAJOR CONSTITUENT OF THE RHODIOLA ROSEA PLANT OF THE FAMILY CRASSULACEAE, IS BELIEVED TO EXHIBIT MULTIPLE PHARMACOLOGICAL EFFECTS ON DIVERSE DISEASES. HOWEVER, ITS EFFECT ON NON-ALCOHOLIC STEATOHEPATITIS (NASH), THE PROGRESSIVE FORM OF NAFLD, AND THE UNDERLYING MECHANISMS ARE NOT FULLY ILLUSTRATED. AIM: INVESTIGATE THE PHARMACOLOGICAL ACTIVITY AND POTENTIAL MECHANISM OF ROSAVIN TREATMENT ON NASH MANAGEMENT VIA TARGETING HEPATIC CELL DEATH-RELATED (HSPD1/TNF/MMP14/ITGB1) MRNAS AND THEIR UPSTREAM NONCODING RNA REGULATORS (MIRNA-6881-5P AND LNC-SPARCL1-1:2) IN NASH RATS. RESULTS: HIGH SUCROSE HIGH FAT (HSHF) DIET-INDUCED NASH RATS WERE TREATED WITH DIFFERENT CONCENTRATIONS OF ROSAVIN (10, 20, AND 30 MG/KG/DAY) FOR THE LAST FOUR WEEKS OF DIETARY MANIPULATION. THE DATA REVEALED THAT ROSAVIN HAD THE ABILITY TO MODULATE THE EXPRESSION OF THE HEPATIC CELL DEATH-RELATED RNA PANEL THROUGH THE UPREGULATION OF BOTH (HSPD1/TNF/MMP14/ITGB1) MRNAS AND THEIR EPIGENETIC REGULATORS (MIRNA-6881-5P AND LNC-SPARCL1-1:2). MOREOVER, ROSAVIN AMELIORATED THE DETERIORATION IN BOTH LIVER FUNCTIONS AND LIPID PROFILE, AND THEREBY IMPROVED THE HEPATIC INFLAMMATION, FIBROSIS, AND APOPTOSIS, AS EVIDENCED BY THE DECREASED PROTEIN LEVELS OF IL6, TNF-ALPHA, AND CASPASE-3 IN LIVER SECTIONS OF TREATED ANIMALS COMPARED TO THE UNTREATED NASH RATS. CONCLUSION: ROSAVIN HAS DEMONSTRATED A POTENTIAL ABILITY TO ATTENUATE DISEASE PROGRESSION AND INHIBIT HEPATIC CELL DEATH IN THE NASH ANIMAL MODEL. THE PRODUCED EFFECT WAS CORRELATED WITH UPREGULATION OF THE HEPATIC CELL DEATH-RELATED (HSPD1, TNF, MMP14, AND ITGB1) MRNAS-(MIRNA-6881-5P-(LNC-SPARCL1-1:2) RNA PANEL. 2022 3 6393 18 THE ROLE OF THE HISTONE METHYLTRANSFERASE EZH2 IN LIVER INFLAMMATION AND FIBROSIS IN STAM NASH MICE. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS A LEADING FORM OF CHRONIC LIVER DISEASE, WITH FEW BIOMARKERS AND TREATMENT OPTIONS CURRENTLY AVAILABLE. NON-ALCOHOLIC STEATOHEPATITIS (NASH), A PROGRESSIVE DISEASE OF NAFLD, MAY LEAD TO FIBROSIS, CIRRHOSIS, AND HEPATOCELLULAR CARCINOMA. EPIGENETIC MODIFICATION CAN CONTRIBUTE TO THE PROGRESSION OF NAFLD CAUSING NON-ALCOHOLIC STEATOHEPATITIS (NASH), IN WHICH THE EXACT ROLE OF EPIGENETICS REMAINS POORLY UNDERSTOOD. TO IDENTIFY POTENTIAL THERAPEUTICS FOR NASH, WE TESTED SMALL-MOLECULE INHIBITORS OF THE EPIGENETIC TARGET HISTONE METHYLTRANSFERASE EZH2, TAZEMETOSTAT (EPZ-6438), AND UNC1999 IN STAM NASH MICE. THE RESULTS DEMONSTRATE THAT TREATMENT WITH EZH2 INHIBITORS DECREASED SERUM TNF-ALPHA IN NASH. IN THIS STUDY, WE INVESTIGATED THAT INHIBITION OF EZH2 REDUCED MRNA EXPRESSION OF INFLAMMATORY CYTOKINES AND FIBROSIS MARKERS IN NASH MICE. IN CONCLUSION, THESE RESULTS SUGGEST THAT EZH2 MAY PRESENT A PROMISING THERAPEUTIC TARGET IN THE TREATMENT OF NASH. 2020 4 3164 26 GREEN TEA PREVENTS NAFLD BY MODULATION OF MIR-34A AND MIR-194 EXPRESSION IN A HIGH-FAT DIET MOUSE MODEL. BACKGROUND/AIMS: NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS CONSIDERED THE HEPATIC MANIFESTATION OF METABOLIC SYNDROME. IT IS CURRENTLY THE MOST COMMON CHRONIC LIVER DISEASE WITH COMPLEX PATHOGENESIS AND CHALLENGING TREATMENT. HERE, WE INVESTIGATED THE HEPATOPROTECTIVE ROLE OF GREEN TEA (GT) AND DETERMINED THE INVOLVEMENT OF MIRNAS AND ITS MECHANISM OF ACTION. METHODS: MALE C57BL/6 MICE WERE FED WITH A HIGH-FAT DIET FOR 4 WEEKS. AFTER THIS PERIOD, THE ANIMALS RECEIVED GAVAGE WITH GT (500 MG/KG BODY WEIGHT) OVER 12 WEEKS (5 DAYS/WEEK). HEPG2 CELL LINES WERE TRANSFECTED WITH MIR-34A OR MIR-194 MIMETICS AND INHIBITORS TO VALIDATE THE IN VIVO RESULTS OR WERE TREATED WITH TNF-ALPHA TO EVALUATE MIRNA REGULATION. RESULTS: GT SUPPLEMENTATION PROTECTS AGAINST NAFLD DEVELOPMENT BY ALTERING LIPID METABOLISM, INCREASING GENE EXPRESSION INVOLVED IN TRIGLYCERIDES AND FATTY ACID CATABOLISM, AND DECREASING UPTAKE AND LIPID ACCUMULATION. THIS PHENOTYPE WAS ACCOMPANIED BY MIR-34A DOWNREGULATION AND AN INCREASE IN THEIR MRNA TARGETS SIRT1, PPARALPHA, AND INSIG2. GT UPREGULATED HEPATIC MIR-194 BY INHIBITING TNF-ALPHA ACTION LEADING TO A DECREASE IN MIR-194 TARGET GENES HMGCS/APOA5. CONCLUSION: OUR STUDY IDENTIFIED FOR THE FIRST TIME THAT THE BENEFICIAL EFFECTS OF GT IN THE LIVER CAN BE DUE TO THE MODULATION OF MIRNAS, OPENING NEW PERSPECTIVES FOR THE TREATMENT OF NAFLD FOCUSING ON EPIGENETIC REGULATION OF MIR-34A AND MIR-194 AS GREEN TEA TARGETS. 2019 5 5234 23 PROFILE ANALYSIS AND FUNCTIONAL MODELING IDENTIFY CIRCULAR RNAS IN NONALCOHOLIC FATTY LIVER DISEASE AS REGULATORS OF HEPATIC LIPID METABOLISM. NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS THE LEADING CAUSE OF CHRONIC LIVER DISEASE, ASSOCIATED WITH AN OUTCOME OF HEPATIC FIBROSIS/CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. HOWEVER, LIMITED EXPLORATION OF THE UNDERLYING MECHANISMS HINDERS ITS PREVENTION AND TREATMENT. TO INVESTIGATE THE MECHANISMS OF EPIGENETIC REGULATION IN NAFLD, THE EXPRESSION PROFILE OF CIRCULAR RNA (CIRCRNA) OF RODENTS IN WHICH NAFLD WAS INDUCED BY A HIGH-FAT, HIGH-CHOLESTEROL (HFHC) DIET WAS STUDIED. MODELING OF THE CIRCRNA-MICRORNA (MIRNA) -MRNA REGULATORY NETWORK REVEALED THE FUNCTIONAL CHARACTERISTICS OF NAFLD-SPECIFIC CIRCRNAS. THE TARGETS AND EFFECTS IN THE LIVER OF SUCH NAFLD-SPECIFIC CIRCRNAS WERE FURTHER ASSESSED. OUR RESULTS UNCOVERED THAT THE DOWNREGULATION OF 28 ANNOTATED CIRCRNAS CHARACTERIZES HFHC DIET-INDUCED NAFLD. AMONG THE DOWNREGULATED CIRCRNAS, LONG INTERGENIC NON-PROTEIN CODING RNA, P53 INDUCED TRANSCRIPT (LNCPINT) -DERIVED CIRCRNAS (CIRC_0001452, CIRC_0001453, AND CIRC_0001454) TARGETED BOTH MIR-466I-3P AND MIR-669C-3P. THEIR DEFICIENCY IN NAFLD ABROGATED THE CIRCRNA-BASED INHIBITORY EFFECT ON BOTH MIRNAS, WHICH FURTHER INACTIVATED THE AMPK SIGNALING PATHWAY VIA AMPK-ALPHA1 SUPPRESSION. INHIBITION OF THE AMPK SIGNALING PATHWAY PROMOTES HEPATIC STEATOSIS, DEPENDING ON THE TRANSCRIPTIONAL AND TRANSLATIONAL UPREGULATION OF LIPOGENIC GENES, SUCH AS THOSE ENCODING STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 (SREBP1) AND FATTY ACID SYNTHASE (FASN) IN HEPATOCYTES. THE LEVELS OF LNCPINT-DERIVED CIRCRNAS DISPLAYED A NEGATIVE ASSOCIATION WITH HEPATIC TRIGLYCERIDE (TG) CONCENTRATION. THESE FINDINGS SUGGEST THAT LOSS OF LNCPINT-DERIVED CIRCRNAS MAY UNDERLIE NAFLD VIA MIR-466I-3P- AND MIR-669C-3P-DEPENDENT INACTIVATION OF THE AMPK SIGNALING PATHWAY. 2022 6 1666 31 DOWNREGULATION OF MICRORNA-145A-5P PROMOTES STEATOSIS-TO-NASH PROGRESSION THROUGH UPREGULATION OF NR4A2. BACKGROUND & AIMS: THE MOLECULAR MECHANISMS UNDERLYING THE PROGRESSION OF SIMPLE STEATOSIS TO NON-ALCOHOLIC STEATOHEPATITIS (NASH) REMAIN INCOMPLETELY UNDERSTOOD, THOUGH THE POTENTIAL ROLE OF EPIGENETIC REGULATION BY MICRORNA (MIRNAS) IS AN AREA OF INCREASING INTEREST. IN THE PRESENT STUDY, WE AIMED TO INVESTIGATE THE ROLE AND MECHANISM OF MIRNAS DURING STEATOSIS-TO-NASH PROGRESSION. METHODS: MIR-145A-5P WAS IDENTIFIED AS AN IMPORTANT CHECKPOINT IN STEATOSIS-TO-NASH PROGRESSION. IN VIVO LOSS-OF-FUNCTION AND GAIN-OF-FUNCTION STUDIES WERE PERFORMED TO EXPLORE THE ROLE OF MIR-145A-5P AND NR4A2 IN NASH PROGRESSION. RNA-SEQUENCING AND BIOINFORMATIC ANALYSIS WERE USED TO INVESTIGATE THE TARGETS OF MIR-145A-5P. RESULTS: SUPPRESSION OF MIR-145A-5P IN THE LIVER AGGRAVATED LIPID ACCUMULATION AND ACTIVATED HEPATIC INFLAMMATION, LIVER INJURY AND FIBROSIS IN STEATOTIC MICE, WHEREAS ITS RESTORATION MARKEDLY ATTENUATED DIET-INDUCED NASH PATHOGENESIS. MECHANISTICALLY, MIR-145A-5P WAS ABLE TO DOWNREGULATE THE NUCLEAR RECEPTOR NR4A2 AND THUS INHIBIT THE EXPRESSION OF NASH-ASSOCIATED GENES. SIMILARLY, NR4A2 OVEREXPRESSION PROMOTED STEATOSIS-TO-NASH PROGRESSION WHILE LIVER-SPECIFIC NR4A2 KNOCKOUT MICE WERE PROTECTED FROM DIET-INDUCED NASH. THIS ROLE OF THE MIR-145A-5P/NR4A2 REGULATORY AXIS WAS ALSO CONFIRMED IN PRIMARY HUMAN HEPATOCYTES. FURTHERMORE, THE EXPRESSION OF MIR-145A-5P WAS REDUCED AND THE EXPRESSION OF NR4A2 WAS INCREASED IN THE LIVERS OF PATIENTS WITH NASH, WHILE THEIR EXPRESSION LEVELS SIGNIFICANTLY NEGATIVELY AND POSITIVELY CORRELATED WITH FEATURES OF LIVER PATHOLOGY, RESPECTIVELY. CONCLUSIONS: OUR FINDINGS HIGHLIGHT THE ROLE OF THE MIR-145A-5P/NR4A2 REGULATORY AXIS IN STEATOSIS-TO-NASH PROGRESSION, SUGGESTING THAT EITHER SUPPLEMENTATION OF MIR-145A-5P OR PHARMACOLOGICAL INHIBITION OF NR4A2 IN HEPATOCYTES MAY PROVIDE A PROMISING THERAPEUTIC APPROACH FOR THE TREATMENT OF NASH. IMPACT AND IMPLICATIONS: NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS A DYNAMIC SPECTRUM OF CHRONIC LIVER DISEASES RANGING FROM SIMPLE STEATOSIS TO NON-ALCOHOLIC STEATOHEPATITIS (NASH). UNFORTUNATELY, THERE ARE CURRENTLY NO APPROVED DRUGS FOR NASH. OUR CURRENT STUDY IDENTIFIED MIR-145A-5P AS A NOVEL REGULATOR THAT INHIBITS STEATOSIS-TO-NASH PROGRESSION. WE FOUND THAT MIR-145A-5P WAS ABLE TO DOWNREGULATE THE NUCLEAR RECEPTOR NR4A2 TO SUPPRESS THE EXPRESSION OF NASH-ASSOCIATED GENES. THE DIFFERENTIAL EXPRESSION OF MIR-145A-5P AND NR4A2 WAS FURTHER CONFIRMED IN PATIENTS WITH NASH, RAISING THE POSSIBILITY THAT SUPPLEMENTATION OF MIR-145A-5P OR SUPPRESSION OF NR4A2 IN HEPATOCYTES MIGHT PROVIDE NOVEL STRATEGIES FOR TREATING NASH. 2023 7 615 34 BIOACTIVE COMPONENTS AND POSSIBLE ACTIVITIES OF MEDICINAL MUSHROOMS IN ALLEVIATING THE PATHOGENESIS OF NONALCOHOLIC FATTY LIVER DISEASE (REVIEW). NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS A GLOBAL DISEASE THAT IS CLOSELY ASSOCIATED WITH OBESITY, TYPE 2 DIABETES MELLITUS, AND CARDIOVASCULAR DISEASE. EXCESSIVE FAT ACCUMULATION, FATTY DEGENERATION, AND CHRONIC INFLAMMATION OF THE LIVER ACTIVATE THE PROGRESSION OF NAFLD FROM SIMPLE STEATOSIS TO NONALCOHOLIC STEATOHEPATITIS AND FURTHER TO LIVER FIBROSIS, CIRRHOSIS, AND HEPATOCELLULAR CARCINOMA. THE UNDERLYING MECHANISM FOR THE DEVELOPMENT AND PROGRESSION OF NAFLD IS COMPLEX AND A MULTIPLE-HIT HYPOTHESIS INCLUDING DIETARY, ENVIRONMENTAL, GENETIC, AND EPIGENETIC FACTORS HAS BEEN RAISED. INCREASED DE NOVO LIPOGENESIS, DECREASED LIPOLYSIS, AND INSULIN RESISTANCE ARE ASSOCIATED WITH THE DEVELOPMENT OF NAFLD. CURRENTLY, NO EFFECTIVE DRUG THERAPIES ARE APPROVED FOR THE TREATMENT OF NAFLD. SEVERAL MEDICINAL MUSHROOMS HAVE BEEN FOUND TO HAVE SIGNIFICANT WEIGHT CONTROL AND GUT MICROBE MODULATION ACTIVITIES AND ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTIOXIDANT, AND ANTI-INFLAMMATORY EFFECTS, WHICH MAY BE USEFUL TO PREVENT AND ATTENUATE THE DEVELOPMENT AND PROGRESSION OF NAFLD. THESE BENEFICIAL EFFECTS ARE ASSOCIATED WITH MUSHROOMS' BIOACTIVE COMPONENTS, SUCH AS POLYSACCHARIDES, DIETARY FIBERS, ANTIOXIDANTS, AND OTHER COMPOUNDS DERIVED FROM FRUITING BODIES, CULTURED MYCELIUM, AND/OR BROTH OF MEDICINAL MUSHROOMS. THIS ARTICLE PRESENTS AN OVERVIEW OF MULTIPLE ASPECTS OF NAFLD, INCLUDING THE EPIDEMIOLOGY, PATHOGENESIS, MANAGEMENT, AND TREATMENT. THE BIOACTIVE COMPONENTS AND POSSIBLE ACTIVITIES OF MEDICINAL MUSHROOMS IN ALLEVIATING THE PATHOGENESIS OF NAFLD ARE ALSO REVIEWED. 2021 8 4108 13 MECHANISMS AND DISEASE CONSEQUENCES OF NONALCOHOLIC FATTY LIVER DISEASE. NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS THE LEADING CHRONIC LIVER DISEASE WORLDWIDE. ITS MORE ADVANCED SUBTYPE, NONALCOHOLIC STEATOHEPATITIS (NASH), CONNOTES PROGRESSIVE LIVER INJURY THAT CAN LEAD TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA. HERE WE PROVIDE AN IN-DEPTH DISCUSSION OF THE UNDERLYING PATHOGENETIC MECHANISMS THAT LEAD TO PROGRESSIVE LIVER INJURY, INCLUDING THE METABOLIC ORIGINS OF NAFLD, THE EFFECT OF NAFLD ON HEPATIC GLUCOSE AND LIPID METABOLISM, BILE ACID TOXICITY, MACROPHAGE DYSFUNCTION, AND HEPATIC STELLATE CELL ACTIVATION, AND CONSIDER THE ROLE OF GENETIC, EPIGENETIC, AND ENVIRONMENTAL FACTORS THAT PROMOTE FIBROSIS PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA IN NASH. 2021 9 5968 25 TERPENOID TREATMENT IN OSTEOPOROSIS: THIS IS WHERE WE HAVE COME IN RESEARCH. LOWER BONE RESISTANCE TO LOAD IS DUE TO THE IMBALANCE OF BONE HOMEOSTASIS, WHERE EXCESSIVE BONE RESORPTION, COMPARED WITH BONE FORMATION, DETERMINES A PROGRESSIVE OSTEOPENIA, LEADING TO A HIGH RISK OF FRACTURES AND CONSEQUENT PAIN AND FUNCTIONAL LIMITATIONS. TERPENOIDS, WITH THEIR ACTIVITIES AGAINST BONE RESORPTION, HAVE RECENTLY RECEIVED INCREASED ATTENTION FROM RESEARCHERS. THEY ARE POTENTIALLY MORE SUITABLE FOR LONG-TERM USE COMPARED WITH TRADITIONAL THERAPEUTICS. IN THIS REVIEW OF THE LITERATURE OF THE PAST 5 YEARS, WE PROVIDE COMPREHENSIVE INFORMATION ON TERPENOIDS, WITH THEIR ANTI-OSTEOPOROTIC EFFECTS, HIGHLIGHTING MOLECULAR MECHANISMS THAT ARE OFTEN IN EPIGENETIC KEY AND A POSSIBLE PHARMACOLOGICAL USE IN OSTEOPOROSIS PREVENTION AND TREATMENT. 2021 10 1721 23 DYSREGULATION OF AUTOPHAGY ACTS AS A PATHOGENIC MECHANISM OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) INDUCED BY COMMON ENVIRONMENTAL POLLUTANTS. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) HAS BEEN THE MOST COMMON CHRONIC LIVER DISEASE IN THE WORLD, INCLUDING THE DEVELOPING COUNTRIES. NAFLD IS METABOLIC DISEASE WITH SIGNIFICANT LIPID DEPOSITION IN THE HEPATOCYTES OF THE LIVER, WHICH IS USUALLY ASSOCIATED WITH OXIDATIVE STRESS, INFLAMMATION AND FIBROGENESIS, AND INSULIN RESISTANCE. PROGRESSIVE NAFLD CAN DEVELOP INTO NON-ALCOHOLIC STEATOHEPATITIS (NASH) OR HEPATOCELLULAR CARCINOMA. THE CURRENT EVIDENCE PROPOSES THAT ENVIRONMENTAL POLLUTANTS PROMOTE DEVELOPMENT AND PROGRESSION OF NAFLD, AND AUTOPHAGY PLAYS A VITAL ROLE BUT IS MULTIFACTORIAL AFFECTED IN NAFLD. IN THIS REVIEW, WE ANALYZED ON THE REGULATIONS OF COMMON ENVIRONMENTAL POLLUTANTS ON AUTOPHAGY IN NAFLD. TO CLARIFY THE INVOLVED ROLES OF AUTOPHAGY, WE DISCUSSED THE DYSREGULATION OF AUTOPHAGY BY ENVIRONMENTAL POLLUTANTS IN ADIPOSE TISSUE AND GUT, AND THEIR INTERACTIONS WITH LIVER, AS WELL AS EPIGENETIC REGULATION ON AUTOPHAGY BY ENVIRONMENTAL POLLUTANTS. FURTHERMORE, PROTECTIVE ROLES OF POTENTIAL THERAPEUTIC TREATMENTS ON THE MULTIPLE-HITS OF AUTOPHAGY IN NAFLD WERE DESCRIPTED. 2021 11 5386 29 REDOX HOMEOSTASIS AND EPIGENETICS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AN ACCUMULATION OF INTRA-HEPATIC TRIGLYCERIDES THAT IS OFTEN CONSIDERED THE HEPATIC MANIFESTATION OF INSULIN RESISTANCE, IS THE MOST COMMON CAUSE OF CHRONIC LIVER DISEASE IN THE WESTERN COUNTRIES WITH UP TO ONE THIRD OF THE POPULATION AFFECTED. NAFLD IS A SPECTRUM OF DISTURBANCES THAT ENCOMPASSES VARIOUS DEGREES OF LIVER DAMAGE RANGING FROM SIMPLE STEATOSIS TO NON-ALCOHOLIC STEATOHEPATITIS (NASH). NASH IS CHARACTERIZED BY HEPATOCELLULAR INJURY/INFLAMMATION WITH OR WITHOUT FIBROSIS. THE INDIVIDUALS WITH NAFLD DEVELOP NASH IN 10% OF THE CASES, AND ARE ALSO AT RISK OF DEVELOPING HEPATOCELLULAR CARCINOMA (HCC). EPIGENETIC MECHANISMS OF NUCLEAR CHROMATIN REMODELING, SUCH AS DNA METHYLATION, POST-TRANSLATIONAL MODIFICATIONS OF HISTONES, AND INCORPORATION OF HISTONE VARIANTS INTO THE CHROMATIN ARE INCREASINGLY RECOGNIZED AS CRUCIAL FACTORS IN THE PATHOPHYSIOLOGY OF NAFLD. NAFLD IS OFTEN ACCOMPANIED BY OXIDATIVE STRESS: REACTIVE OXYGEN SPECIES (ROS) ARE IMPLICATED IN ALTERED REDUCTION/OXIDATION (REDOX) REACTIONS THAT ATTACK CELLULAR MACROMOLECULES AND ARE DETECTED IN THE LIVER OF PATIENTS AND ANIMAL MODELS OF NAFLD. IN THIS REVIEW, WE SUMMARIZE RECENT KNOWLEDGE ADVANCEMENTS IN THE HEPATIC EPIGENETIC AND REDOX MECHANISMS, AND THEIR POSSIBLE LINKS, INVOLVED IN THE PATHOGENESIS AND TREATMENT OF NAFLD. 2013 12 5850 24 SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) REDUCES FIBROSIS MARKERS AND DEACTIVATES HUMAN STELLATE CELLS VIA THE EPITHELIAL-MESENCHYMAL TRANSITION (EMT). HEPATIC FIBROSIS IS KNOWN AS THE ACCUMULATION OF CONNECTIVE TISSUE SECONDARY TO CHRONIC DAMAGE TO THE LIVER. EPITHELIAL-MESENCHYMAL TRANSITION (EMT) CORRESPONDING INCREASE IN LIVER FIBROGENESIS WAS SHOWN WITH IMMUNOHISTOCHEMISTRY AND PCR-BASED STUDIES. SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), A SYNTHETIC COMPOUND APPROVED AS A HISTONE DEACETYLASE INHIBITOR (HDAC) BY THE FDA TO TREAT CUTANEOUS T-CELL LYMPHOMA IS UNDER INVESTIGATION FOR THE TREATMENT OF LUNG AND RENAL FIBROSIS. EXPERIMENTAL MODELING FOR HEPATIC FIBROSIS CAN BE CONSTRUCTED WITH AN LX2 CELL LINE ISOLATED FROM HUMAN HEPATIC STELLATE CELLS (HSCS). IN THIS STUDY, WE AIMED TO INVESTIGATE THE MODULATION OF SAHA IN THE PATHOGENESIS OF LIVER FIBROSIS BY DETECTING THE LEVELS OF PROTEINS; (E-CADHERIN (E-CAD), N-CADHERIN (N-CAD), VIMENTIN (VIM), AND GENES; E-CAD, N-CAD, VIM, TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA), ALPHA-SMOOTH MUSCLE ACTIN (ALPHA-SMA), TYPE 1 COLLAGEN (COL1A1), TYPE 3 COLLAGEN (COL3A1)) THAT PLAY A SIGNIFICANT ROLE IN EMT WITH THE LX2 CELL LINE. WE ALSO EVALUATED THE ACTION OF SAHA WITH CELL PROLIFERATION, CLONOGENIC, AND MIGRATION ASSAY. CELL PROLIFERATION WAS PERFORMED BY FLOW CYTOMETRY. ALL THE PROTEIN LEVELS WERE DETERMINED BY WESTERN BLOT ANALYSIS, AND GENE EXPRESSION LEVELS WERE MEASURED BY REAL-TIME PCR. OUR STUDY OBSERVED THAT SAHA TREATMENT DECREASED CELL VIABILITY, COLONY FORMATION AND MIGRATION IN LX2 CELLS. WE FOUND THAT SAHA INCREASED E-CAD EXPRESSION LEVEL, WHILE IT DECREASED N-CAD, VIM, COL1A1, COL3A1, ALPHA-SMA TGF-BETA GENES EXPRESSION LEVELS. SAHA DECREASED THE LEVEL OF E-CAD, N-CAD, AND VIM PROTEIN LEVELS. WE THOUGHT THAT SAHA POSSESSES POTENT ANTIFIBROTIC AND ANTI-EMT PROPERTIES IN LX2. 2021 13 4747 21 NOVEL MODULATORS OF HEPATOSTEATOSIS, INFLAMMATION AND FIBROGENESIS. ALCOHOLIC STEATOSIS, INSTEAD OF BEING INNOCUOUS, PLAYS A CRITICAL ROLE IN LIVER INFLAMMATION AND FIBROGENESIS. THE SEVERITY OF FATTY LIVER IS GOVERNED BY THE CONCERTED BALANCE BETWEEN LIPID TRANSPORT, SYNTHESIS, AND DEGRADATION. WHEREAS SCAVENGER RECEPTOR CLASS B, TYPE I (SR-B1) IS CRITICAL FOR REVERSE CHOLESTEROL UPTAKE BY THE LIVER, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA (PPARGAMMA) COACTIVATOR-1ALPHA AND -BETA (PGC1ALPHA AND PGC1BETA) ARE CRITICAL FOR LIPID DEGRADATION AND SYNTHESIS, RESPECTIVELY. BECAUSE BETAINE IS A LIPOTROPIC AGENT, WE HAVE EVALUATED ITS EFFECTS ON ALCOHOLIC STEATOSIS. BETAINE EFFECTIVELY PREVENTED CHRONIC ALCOHOL-MEDIATED (I) IMPAIRED SR-B1 GLYCOSYLATION, PLASMA MEMBRANE LOCALIZATION, AND CONSEQUENT IMPAIRED CHOLESTEROL TRANSPORT; AND (II) UP REGULATION OF PGC-1BETA, STEROL REGULATORY ELEMENT-BINDING PROTEIN 1C AND DOWNSTREAM LIPOGENIC GENES WITH CONCOMITANT INCREASED LIVER CHOLESTEROL, TRIGLYCERIDES AND HEPATIC LIPID SCORE. SIMILARLY, BECAUSE OF ITS ANTI-INFLAMMATORY AND ANTI-FIBROTIC EFFECTS IN OTHER ORGANS, WE EVALUATED THE PROTECTIVE EFFECTS OF THYMOSIN BETA4 (TBETA4) AGAINST CARBON TETRACHLORIDE (CCL4)-INDUCED HEPATOTOXICITY IN RAT. TBETA4 PREVENTED CCL4-INDUCED (I) NECROSIS, INFLAMMATORY INFILTRATION AND UP-REGULATION OF ALPHA1(2)COLLAGEN, ALPHA-SMOOTH MUSCLE ACTIN (ALPHA-SMA), PLATELET DERIVED GROWTH FACTOR BETA (PDGF-BETA) RECEPTOR AND FIBRONECTIN MRNA EXPRESSION; (II) DOWN-REGULATION OF ADIPOGENIC GENE, PPARGAMMA AND THE UP-REGULATION OF EPIGENETIC REPRESSOR GENE, METHYL CPG BINDING PROTEIN 2 (MECP2) MRNA LEVELS, SUGGESTING THAT THE ANTI-FIBROGENIC ACTIONS OF TBETA4 INVOLVE THE PREVENTION OF TRANS-DIFFERENTIATION OF QUIESCENT HEPATIC STELLATE CELLS INTO MYO-FIBROBLASTS LARGELY BY UP-REGULATING PPARGAMMA AND BY DOWN-REGULATING MECP2 GENES. WE THEREFORE CONCLUDE THAT BETAINE AND TBETA4 CAN EFFECTIVELY PROTECT AGAINST ALCOHOLIC HEPATOSTEATOSIS AND HEPATIC FIBROGENESIS, RESPECTIVELY. 2014 14 6436 30 THERAPEUTIC ACTIONS OF TEA PHENOLIC COMPOUNDS AGAINST OXIDATIVE STRESS AND INFLAMMATION AS CENTRAL MEDIATORS IN THE DEVELOPMENT AND PROGRESSION OF HEALTH PROBLEMS: A REVIEW FOCUSING ON MICRORNA REGULATION. MANY HEALTH PROBLEMS INCLUDING CHRONIC DISEASES ARE CLOSELY ASSOCIATED WITH OXIDATIVE STRESS AND INFLAMMATION. TEA HAS ABUNDANT PHENOLIC COMPOUNDS WITH VARIOUS HEALTH BENEFITS INCLUDING ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES. THIS REVIEW FOCUSES ON THE PRESENT UNDERSTANDING OF THE IMPACT OF TEA PHENOLIC COMPOUNDS ON THE EXPRESSION OF MIRNAS, AND ELUCIDATES THE BIOCHEMICAL AND MOLECULAR MECHANISMS UNDERLYING THE TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL PROTECTIVE ACTIONS OF TEA PHENOLIC COMPOUNDS AGAINST OXIDATIVE STRESS- AND/OR INFLAMMATION-MEDIATED DISEASES. CLINICAL STUDIES SHOWED THAT DRINKING TEA OR TAKING CATECHIN SUPPLEMENT ON A DAILY BASIS PROMOTED THE ENDOGENOUS ANTIOXIDANT DEFENSE SYSTEM OF THE BODY WHILE INHIBITING INFLAMMATORY FACTORS. THE REGULATION OF CHRONIC DISEASES BASED ON EPIGENETIC MECHANISMS, AND THE EPIGENETIC-BASED THERAPIES INVOLVING DIFFERENT TEA PHENOLIC COMPOUNDS, HAVE BEEN INSUFFICIENTLY STUDIED. THE MOLECULAR MECHANISMS AND APPLICATION STRATEGIES OF MIR-27 AND MIR-34 INVOLVED IN OXIDATIVE STRESS RESPONSE AND MIR-126 AND MIR-146 INVOLVED IN INFLAMMATION PROCESS WERE PRELIMINARILY INVESTIGATED. SOME EMERGING EVIDENCE SUGGESTS THAT TEA PHENOLIC COMPOUNDS MAY PROMOTE EPIGENETIC CHANGES, INVOLVING NON-CODING RNA REGULATION, DNA METHYLATION, HISTONE MODIFICATION, UBIQUITIN AND SUMO MODIFICATIONS. HOWEVER, EPIGENETIC MECHANISMS AND EPIGENETIC-BASED DISEASE THERAPIES INVOLVING PHENOLIC COMPOUNDS FROM DIFFERENT TEAS, AND THE POTENTIAL CROSS-TALKS AMONG THE EPIGENETIC EVENTS, REMAIN UNDERSTUDIED. 2023 15 5460 23 RESEARCH PERSPECTIVES ON THE REGULATION AND PHYSIOLOGICAL FUNCTIONS OF FGF21 AND ITS ASSOCIATION WITH NAFLD. FIBROBLAST GROWTH FACTOR 21 (FGF21) IS A METABOLIC HORMONE PRIMARILY SECRETED FROM THE LIVER AND FUNCTIONS IN MULTIPLE TISSUES. VARIOUS TRANSCRIPTION FACTORS INDUCE FGF21 EXPRESSION IN THE LIVER, WHICH INDICATES THAT FGF21 IS A MEDIATOR OF MULTIPLE ENVIRONMENTAL CUES. FGF21 ALTERS METABOLISM UNDER STARVATION CONDITIONS, PROTECTS THE BODY FROM ENERGY DEPLETION, AND EXTENDS LIFE SPAN. PHARMACOLOGICAL ADMINISTRATION OF FGF21 ALLEVIATES DYSLIPIDEMIA AND INDUCES WEIGHT LOSS IN OBESE ANIMALS. IN ADDITION TO THE WELL-STUDIED FUNCTIONS OF FG21, SEVERAL LINES OF RECENT EVIDENCE INDICATE A POSSIBLE LINK BETWEEN FGF21 AND NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). HIGH SERUM LEVELS OF FGF21 ARE ASSOCIATED WITH NAFLD AND ITS RISK FACTORS, SUCH AS ENDOPLASMIC RETICULUM STRESS AND CHRONIC INFLAMMATION. IN ADDITION, FGF21 ALLEVIATES THE MAJOR RISK FACTORS OF NAFLD, INCLUDING OBESITY, DYSLIPIDEMIA, AND INSULIN INSENSITIVITY. THUS, FGF21 IS A POTENTIAL DRUG CANDIDATE FOR DISEASES, SUCH AS NAFLD, DYSLIPIDEMIA, AND TYPE 2 DIABETES. IN THIS REVIEW, THE RESEARCH PERSPECTIVES OF FGF21 AND THERAPEUTIC POTENCIES OF FGF21 AS A MODULATOR OF NAFLD ARE SUMMARIZED. 2015 16 2862 31 FRUCTOSE-MEDIATED EFFECTS ON GENE EXPRESSION AND EPIGENETIC MECHANISMS ASSOCIATED WITH NAFLD PATHOGENESIS. NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS A CHRONIC, FREQUENTLY PROGRESSIVE CONDITION THAT DEVELOPS IN RESPONSE TO EXCESSIVE HEPATOCYTE FAT ACCUMULATION (I.E., STEATOSIS) IN THE ABSENCE OF SIGNIFICANT ALCOHOL CONSUMPTION. LIVER STEATOSIS DEVELOPS AS A RESULT OF IMBALANCED LIPID METABOLISM, DRIVEN LARGELY BY INCREASED RATES OF DE NOVO LIPOGENESIS AND HEPATIC FATTY ACID UPTAKE AND REDUCED FATTY ACID OXIDATION AND/OR DISPOSAL TO THE CIRCULATION. FRUCTOSE IS A NATURALLY OCCURRING SIMPLE SUGAR, WHICH IS MOST COMMONLY CONSUMED IN MODERN DIETS IN THE FORM OF SUCROSE, A DISACCHARIDE COMPRISED OF ONE MOLECULE OF FRUCTOSE COVALENTLY BONDED WITH ONE MOLECULE OF GLUCOSE. A NUMBER OF OBSERVATIONAL AND EXPERIMENTAL STUDIES HAVE DEMONSTRATED DETRIMENTAL EFFECTS OF DIETARY FRUCTOSE CONSUMPTION NOT ONLY ON DIVERSE METABOLIC OUTCOMES SUCH AS INSULIN RESISTANCE AND OBESITY, BUT ALSO ON HEPATIC STEATOSIS AND NAFLD-RELATED FIBROSIS. DESPITE THE COMPELLING EVIDENCE THAT EXCESSIVE FRUCTOSE CONSUMPTION IS ASSOCIATED WITH THE PRESENCE OF NAFLD AND MAY EVEN PROMOTE THE DEVELOPMENT AND PROGRESSION OF NAFLD TO MORE CLINICALLY SEVERE PHENOTYPES, THE MOLECULAR MECHANISMS BY WHICH FRUCTOSE ELICITS EFFECTS ON DYSREGULATED LIVER METABOLISM REMAIN UNCLEAR. EMERGING DATA SUGGEST THAT DIETARY FRUCTOSE MAY DIRECTLY ALTER THE EXPRESSION OF GENES INVOLVED IN LIPID METABOLISM, INCLUDING THOSE THAT INCREASE HEPATIC FAT ACCUMULATION OR REDUCE HEPATIC FAT REMOVAL. THE AIM OF THIS REVIEW IS TO SUMMARIZE THE CURRENT RESEARCH SUPPORTING A ROLE FOR DIETARY FRUCTOSE INTAKE IN THE MODULATION OF TRANSCRIPTOMIC AND EPIGENETIC MECHANISMS UNDERLYING THE PATHOGENESIS OF NAFLD. 2020 17 4464 24 MOLECULAR MECHANISMS OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)/NONALCOHOLIC STEATOHEPATITIS (NASH). NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ONE OF THE MOST COMMON CHRONIC LIVER DISEASES WORLDWIDE AND HAS GARNERED INCREASING ATTENTION IN RECENT DECADES. NAFLD IS CHARACTERIZED BY A WIDE RANGE OF LIVER CHANGES, FROM SIMPLE STEATOSIS TO NONALCOHOLIC STEATOHEPATITIS (NASH), CIRRHOSIS, AND HEPATOCELLULAR CARCINOMA. THE PATHOGENESIS OF NAFLD/NASH IS VERY COMPLICATED AND INVOLVES LIPID ACCUMULATION, INSULIN RESISTANCE, INFLAMMATION, AND FIBROGENESIS. IN ADDITION, NAFLD IS CLOSELY ASSOCIATED WITH COMPLICATIONS SUCH AS OBESITY, DYSLIPIDEMIA, AND TYPE 2 DIABETES. IN PARTICULAR, THE CLINICAL SPECTRUM, PATHOPHYSIOLOGY, AND THERAPEUTIC OPTIONS OF NAFLD SHARE MANY THINGS IN COMMON WITH DIABETES. INSULIN RESISTANCE IS AN UNDERLYING BASIS FOR THE PATHOGENESIS OF DIABETES AND NAFLD. THIS CHAPTER FOCUSES ON THE MOLECULAR MECHANISM INVOLVED IN THE PATHOGENESIS OF INSULIN RESISTANCE, DIABETES, AND NASH/NAFLD INCLUDING THOSE THAT DRIVE DISEASE PROGRESSION SUCH AS OXIDATIVE STRESS, GENETIC AND EPIGENETIC MECHANISMS, ADIPONECTIN, CYTOKINES, AND IMMUNE CELLS. 2021 18 4880 22 OVERVIEW OF MMP-13 AS A PROMISING TARGET FOR THE TREATMENT OF OSTEOARTHRITIS. OSTEOARTHRITIS (OA) IS A COMMON DEGENERATIVE DISEASE CHARACTERIZED BY THE DESTRUCTION OF ARTICULAR CARTILAGE AND CHRONIC INFLAMMATION OF SURROUNDING TISSUES. MATRIX METALLOPROTEINASE-13 (MMP-13) IS THE PRIMARY MMP INVOLVED IN CARTILAGE DEGRADATION THROUGH ITS PARTICULAR ABILITY TO CLEAVE TYPE II COLLAGEN. HENCE, IT IS AN ATTRACTIVE TARGET FOR THE TREATMENT OF OA. HOWEVER, THE DETAILED MOLECULAR MECHANISMS OF OA INITIATION AND PROGRESSION REMAIN ELUSIVE, AND, CURRENTLY, THERE ARE NO INTERVENTIONS AVAILABLE TO RESTORE DEGRADED CARTILAGE. THIS REVIEW FULLY ILLUSTRATES THE INVOLVEMENT OF MMP-13 IN THE INITIATION AND PROGRESSION OF OA THROUGH THE REGULATION OF MMP-13 ACTIVITY AT THE MOLECULAR AND EPIGENETIC LEVELS, AS WELL AS THE STRATEGIES THAT HAVE BEEN EMPLOYED AGAINST MMP-13. THE AIM OF THIS REVIEW IS TO IDENTIFY MMP-13 AS AN ATTRACTIVE TARGET FOR INHIBITOR DEVELOPMENT IN THE TREATMENT OF OA. 2021 19 616 32 BIOACTIVE COMPOUNDS IN OXIDATIVE STRESS-MEDIATED DISEASES: TARGETING THE NRF2/ARE SIGNALING PATHWAY AND EPIGENETIC REGULATION. OXIDATIVE STRESS IS A PATHOLOGICAL CONDITION OCCURRING DUE TO AN IMBALANCE BETWEEN THE OXIDANTS AND ANTIOXIDANT DEFENSE SYSTEMS IN THE BODY. NUCLEAR FACTOR E2-RELATED FACTOR 2 (NRF2), ENCODED BY THE GENE NFE2L2, IS THE MASTER REGULATOR OF PHASE II ANTIOXIDANT ENZYMES THAT PROTECT AGAINST OXIDATIVE STRESS AND INFLAMMATION. NRF2/ARE SIGNALING HAS BEEN CONSIDERED AS A PROMISING TARGET AGAINST OXIDATIVE STRESS-MEDIATED DISEASES LIKE DIABETES, FIBROSIS, NEUROTOXICITY, AND CANCER. THE CONSUMPTION OF DIETARY PHYTOCHEMICALS ACTS AS AN EFFECTIVE MODULATOR OF NRF2/ARE IN VARIOUS ACUTE AND CHRONIC DISEASES. IN THE PRESENT REVIEW, WE DISCUSSED THE ROLE OF NRF2 IN DIABETES, ALZHEIMER'S DISEASE (AD), PARKINSON'S DISEASE (PD), CANCER, AND ATHEROSCLEROSIS. ADDITIONALLY, WE DISCUSSED THE PHYTOCHEMICALS LIKE CURCUMIN, QUERCETIN, RESVERATROL, EPIGALLOCATECHIN GALLATE, APIGENIN, SULFORAPHANE, AND URSOLIC ACID THAT HAVE EFFECTIVELY MODIFIED NRF2 SIGNALING AND PREVENTED VARIOUS DISEASES IN BOTH IN VITRO AND IN VIVO MODELS. BASED ON THE LITERATURE, IT IS CLEAR THAT DIETARY PHYTOCHEMICALS CAN PREVENT DISEASES BY (1) BLOCKING OXIDATIVE STRESS-INHIBITING INFLAMMATORY MEDIATORS THROUGH INHIBITING KEAP1 OR ACTIVATING NRF2 EXPRESSION AND ITS DOWNSTREAM TARGETS IN THE NUCLEUS, INCLUDING HO-1, SOD, AND CAT; (2) REGULATING NRF2 SIGNALING BY VARIOUS KINASES LIKE GSK3BETA, PI3/AKT, AND MAPK; AND (3) MODIFYING EPIGENETIC MODULATION, SUCH AS METHYLATION, AT THE NRF2 PROMOTER REGION; HOWEVER, FURTHER INVESTIGATION INTO OTHER UPSTREAM SIGNALING MOLECULES LIKE NRF2 AND THE EFFECT OF PHYTOCHEMICALS ON THEM STILL NEED TO BE INVESTIGATED IN THE NEAR FUTURE. 2021 20 4326 21 MICRORNAS IN THE PATHOGENESIS OF NONALCOHOLIC FATTY LIVER DISEASE. NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), OR, MORE ACCURATELY, METABOLIC ASSOCIATED FATTY LIVER DISEASE, ACCOUNTS FOR A LARGE PROPORTION OF CHRONIC LIVER DISORDERS WORLDWIDE AND IS CLOSELY ASSOCIATED WITH OTHER CONDITIONS SUCH AS CARDIOVASCULAR DISEASE, OBESITY, AND TYPE 2 DIABETES MELLITUS. NAFLD RANGES FROM SIMPLE STEATOSIS TO NONALCOHOLIC STEATOHEPATITIS (NASH) AND CAN PROGRESS TO CIRRHOSIS AND, EVENTUALLY, ALSO HEPATOCELLULAR CARCINOMA. THE MORBIDITY AND MORTALITY ASSOCIATED WITH NAFLD ARE INCREASING RAPIDLY YEAR ON YEAR. CONSEQUENTLY, THERE IS AN URGENT NEED TO UNDERSTAND THE ETIOLOGY AND PATHOGENESIS OF NAFLD AND IDENTIFY EFFECTIVE THERAPEUTIC TARGETS. MICRORNAS (MIRNAS), IMPORTANT EPIGENETIC FACTORS, HAVE RECENTLY BEEN PROPOSED TO PARTICIPATE IN NAFLD PATHOGENESIS. HERE, WE REVIEW THE ROLES OF MIRNAS IN LIPID METABOLISM, INFLAMMATION, APOPTOSIS, FIBROSIS, HEPATIC STELLATE CELL ACTIVATION, INSULIN RESISTANCE, AND OXIDATIVE STRESS, KEY FACTORS THAT CONTRIBUTE TO THE OCCURRENCE AND PROGRESSION OF NAFLD. ADDITIONALLY, WE SUMMARIZE THE ROLE OF MIRNA-ENRICHED EXTRACELLULAR VESICLES IN NAFLD. THESE MIRNAS MAY COMPRISE SUITABLE THERAPEUTIC TARGETS FOR THE TREATMENT OF THIS CONDITION. 2021